Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20077689 | 0.69 | KMT2A (0.33) | KMT2A | |
| SCHEMBL3679547 | 0.69 | — | — | |
| SCHEMBL5159191 | 0.69 | KMT2A (0.45) | KMT2AALDH1A1 | |
| SCHEMBL13742897 | 0.67 | ALDH1A1 (0.36) | KMT2AALDH1A1 | |
| SCHEMBL14507507 | 0.65 | — | — | |
| SCHEMBL5449927 | 0.65 | KMT2A (0.41) | KMT2AALDH1A1 | |
| SCHEMBL8942251 | 0.65 | KMT2A (0.35) | KMT2AALDH1A1 | |
| SCHEMBL28064327 | 0.65 | — | — | |
| SCHEMBL3813005 | 0.61 | — | — | |
| SCHEMBL2968811 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215838-A1 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090048219-A1 | ORGANIC NITRIC OXIDE DONOR SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20080293678-A1 | Organic Nitric Oxide Donor Salts of Angiotensin Converting Enzyme Inhibitors, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048219-A1 | ORGANIC NITRIC OXIDE DONOR SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NOS3, NOS1, NOS2 | KMT2A 4643/4885ALDH1A1 630/4885 |
| US-20090215838-A1 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NOS2, NOS3, NOS1 | KMT2A 3944/4885ALDH1A1 1240/4885 |
| US-20080293678-A1 | Organic Nitric Oxide Donor Salts of Angiotensin Converting Enzyme Inhibitors, Compositions and Methods of Use | NOS3, REN, NOS1 | KMT2A 4143/4885ALDH1A1 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.